$DHR (Danaher Corp.)

$DHR {{ '2015-11-02T19:46:09+0000' | timeago}} • SEC

As of Oct. 2, 2015, $DHR held about $1.8Bil of cash and cash equivalents that were invested in highly liquid investment grade debt instruments with a maturity of 90 days or less with an approx. weighted average annual interest rate of 0.3%. Of this amount, $413MM was held within the U.S. and about $1.4Bil was held outside of the U.S.

$DHR {{ '2017-07-20T15:06:40+0000' | timeago}} • Webcast

With nearly $900MM of free cash flow and strong conversion in 2Q17, $DHR is optimistic on further acqusitions. Adding to its strong cash flow, $DHR has $500MM to $1Bil worth of opportunities slated for 2H17. Notably, the company's two most recent large acquisitions, Pall and Cepheid, continues to perform well and became part of the core revenue.

$DHR {{ '2017-07-20T13:00:10+0000' | timeago}} • Announcement

For 3Q17, $DHR sees its GAAP EPS to range from $0.74 to $0.78 and non-GAAP EPS to range from $0.92 to $0.96. For FY17, GAAP EPS to range from $3.16 to $3.23 and non-GAAP EPS to range from $3.90 to $3.97.

$DHR {{ '2017-07-20T12:56:52+0000' | timeago}} • Announcement

$DHR, a science and technology company, reported a 15% YoY drop in net earnings for 2Q17 to $557.3MM, or $0.79 per share. Earnings, adjusted for one-time gains and costs, grew 10% to $0.99 per share. Sales rose 6% to $4.5Bil.

$DHR {{ '2017-07-20T12:12:31+0000' | timeago}} • Infographic

$DHR Danaher Corp. Earnings AlphaGraphic: Q2 2017 Highlights

$DHR {{ '2017-06-20T13:47:35+0000' | timeago}} • Announcement

$DHR's subsidiary DH Europe Finance priced an offering of EUR250MM of floating rate senior notes due 2022 at an offering price of 100.147% of the principal amount; and EUR600MM of 1.200% senior notes due 2027 at an offering price of 99.682% of the principal amount. The offering is expected to close on June 30, 2017.

$DHR {{ '2017-04-20T12:58:57+0000' | timeago}} • Webcast

$DHR is confident about its position in China across all of its five platforms and the opportunities ahead for sustained double-digit growth performance. Dental business continues to drive consistent double-digit growth in each quarter for quite sometime. $DHR added that water quality business had good performance so far this year in China.

$DHR {{ '2017-04-20T10:21:58+0000' | timeago}} • Announcement

$DHR expects 2Q17 EPS of $0.77-0.80 and adjusted EPS of $0.95-0.98. For 2017, the company still sees EPS of $3.13-3.23 and adjusted EPS of $3.85-3.95. Through focused execution across the portfolio, and with Business System continuing to serve as foundation, $DHR sees tremendous opportunities to deliver long-term value creation.

$DHR {{ '2017-04-20T10:19:32+0000' | timeago}} • Announcement

$DHR reported a drop in 1Q17 earnings hurt by higher costs and expenses as well as last year's gain on sale of investments. Net income fell to $506.1MM or $0.72 per share from $758.4MM or $1.09 per share last year. Sales grew to $4.21Bil from $3.92Bil. Adjusted EPS increased to $0.85 from $0.79.

$DHR {{ '2017-02-22T12:54:51+0000' | timeago}} • Announcement

$DHR said it has appointed Raymond Stevens to its BoD. Stevens is currently Provost Professor of Biological Sciences and Chemistry, and Director of The Bridge Institute, at the University of Southern California.

$DHR {{ '2017-01-31T19:38:32+0000' | timeago}} • Webcast

In Life Sciences, $DHR’s reported revenue was up 6% and core revenue grew 4% during 4Q16. In Diagnostics, reported revenue increased 11% and core revenue increased 3%. In the Dental segment, reported and core revenues increased 50BP. In Environmental & Applied Solutions, reported revenue grew 3.5% with core revenue up 4%.

$DHR {{ '2017-01-31T19:28:14+0000' | timeago}} • Webcast

In 4Q16, $DHR’s sales grew 6% with core revenue increasing 3.5%. The impact of currency translation decreased revenues by 1.5% while acquisitions increased revenues by 4%. High-growth markets revenue was up high single digits. Developed market core revenues were up low single digits, led by growth in the US and Western Europe.

$DHR {{ '2017-01-31T14:15:10+0000' | timeago}} • Announcement

$DHR expects 1Q17 EPS of $0.64-0.67 and adjusted EPS of $0.82-0.85. For the full year 2017, $DHR predicts EPS of $3.13-3.23 and adjusted EPS of $3.85-3.95.

$DHR {{ '2017-01-31T14:13:26+0000' | timeago}} • Announcement

$DHR reported a rise in 4Q16 earnings driven by higher sales, and meaningful margin expansion. Net income rose to $747MM or $1.07 per share from $688.6MM or $0.99 per share last year. Sales grew to $4.58Bil from $4.32Bil. Adjusted EPS increased 15.5% to $1.05.

$DHR {{ '2016-12-15T14:21:14+0000' | timeago}} • Announcement

$DHR said it anticipates its FY17 diluted net EPS to be about $3.13 to 3.23. The company expects its non-GAAP adjusted net EPS to be about $3.85 to 3.95, which assumes non-GAAP core revenue growth to be about 3-4%.

$DHR {{ '2016-12-01T14:35:52+0000' | timeago}} • Announcement

$DHR promoted Rainer Blair to EVP, with responsibility for the company's $5Bil Life Sciences platform, effective Jan. 1, 2017. In his new role, Blair will report directly to CEO Thomas Joyce Jr.

$NDSN {{ '2016-11-28T14:25:50+0000' | timeago}} • Announcement

The BoD of $NDSN has elected Stephen P. Lovass as Corporate Vice President for its Industrial Coating Systems (ICS) business segment. He succeeds Douglas C. Bloomfield who will retire at the end of 2016. Mr. Lovass joins $NDSN from $DHR and he has also previously worked with Gerber Scientific Inc.

$DHR {{ '2016-11-07T12:04:18+0000' | timeago}} • Announcement

$DHR closed purchase of $CPHD. Copper Merger Sub, a subsidiary of $DHR, has merged into $CPHD and $CPHD has become an indirect wholly owned subsidiary of $DHR. $CPHD's common stock will cease to be traded on Nasdaq Stock Market.

$FTV {{ '2016-10-27T22:15:00+0000' | timeago}} • Announcement

$FTV, the diversified industrial growth company that operated as part of $DHR prior to July 2, 2016, reported a jump in 3Q16 earnings on higher sales. Net income rose to $226.9MM or $0.65 per share from $196.6MM or $0.57 per share last year. Sales grew 2.8% to $1.57Bil. Adjusted earnings were $233.1MM or $0.67 for 3Q16.

$DHR {{ '2016-10-20T11:36:30+0000' | timeago}} • Announcement

$DHR forecast 4Q16 earnings of $0.85 to $0.89. For the full year 2016, the company anticipates EPS to be $2.86 to $2.90. $DHR said its recent acquisitions of Cepheid and Phenomenex will boost its Diagnostics and Life Sciences segments, respectively, thus enhancing its positioning and broadening the product offerings.

$DHR {{ '2016-10-20T11:33:00+0000' | timeago}} • Announcement

$DHR reported a higher 3Q16 profit from continuing operations on higher revenue. The company reported earnings of $402.6MM, or $0.57 per share, which was up 6% from a year ago. Revenue rose 7.5% to $4.1Bil.

Recent Transcripts

DHR (Danaher Corp.)
Thursday, July 20 2017 - 12:00pm
FCEL (FuelCell Energy Inc.)
Thursday, June 8 2017 - 2:00pm
THR (Thermon Group Holdings, Inc.)
Wednesday, May 24 2017 - 3:00pm
TGI (Triumph Group, Inc.)
Wednesday, May 24 2017 - 12:30pm
AZO (AutoZone, Inc.)
Tuesday, May 23 2017 - 2:00pm
UQM (UQM Technologies Inc.)
Thursday, May 11 2017 - 8:30pm
VRML (Vermillion, Inc.)
Thursday, May 11 2017 - 12:30pm
HWCC (Houston Wire & Cable Company)
Wednesday, May 10 2017 - 3:00pm
TSLA (Tesla, Inc.)
Wednesday, May 3 2017 - 9:30pm
LDL (Lydall, Inc.)
Wednesday, May 3 2017 - 7:30pm
HSC (Harsco Corporation)
Wednesday, May 3 2017 - 1:00pm
BLDP (Ballard Power Systems Inc.)
Tuesday, May 2 2017 - 3:00pm
HLIT (Harmonic Inc.)
Monday, May 1 2017 - 9:00pm
FLT (FleetCor Technologies, Inc.)
Monday, May 1 2017 - 9:00pm
CGNX (Cognex Corporation)
Monday, May 1 2017 - 9:00pm
B (Barnes Group Inc.)
Friday, April 28 2017 - 12:30pm
ROP (Roper Technologies, Inc.)
Friday, April 28 2017 - 12:30pm
SNE (Sony Corporation)
Friday, April 28 2017 - 8:15am
GPRO (GoPro, Inc.)
Thursday, April 27 2017 - 9:00pm
ABAX (Abaxis, Inc.)
Thursday, April 27 2017 - 8:15pm

AlphaGraphics you may like